- In August 2022, Processa Pharmaceuticals, Inc. initiated its Phase 2A clinical trial for PCS12852, enrolling its first patient with moderate to severe gastroparesis
- In February 2022, Vanda Pharmaceuticals Inc. (Vanda) shared the Phase III clinical trial outcomes, VP-VLY-686-3303, revealing the effectiveness and safety of tradipitant in addressing gastroparesis symptoms
